AlphaQuest’s Denali Therapeutics DNLI Stock Holding History

AlphaQuest’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,909	Closed	-$708K	–	581
2025 Q4	$708K	Sell	42,909 -31,513	-42%	-$532K	0.04%	603
2025 Q3	$1.08M	Buy	74,422 +51,458	+224%	+$739K	0.07%	402
2025 Q2	$321K	Sell	22,964 -2,096	-8%	-$29.5K	0.03%	843
2025 Q1	$341K	Buy	25,060 +18,099	+260%	+$347K	0.04%	697
2024 Q4	$142K	Buy	6,961 +4,449	+177%	+$114K	0.02%	991
2024 Q3	$73.2K	Buy	+2,512	New	+$62.3K	0.01%	1351
2024 Q1	–	Sell	-9,965	Closed	-$214K	–	1687
2023 Q4	$214K	Buy	+9,965	New	+$197K	0.05%	595

Other funds holding DNLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AlphaQuest's DNLI Position: Q1 2026 in Review

AlphaQuest sold out of Denali Therapeutics (DNLI) in Q1 2026, closing a stake of 42,909 shares — an estimated $708K sold.

AlphaQuest first reported a position in DNLI in Q4 2023 and held it in 7 quarters. The position peaked at $1.08M in Q3 2025. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

AlphaQuest reported no remaining Denali Therapeutics position as of Q1 2026 after selling out during the quarter.
AlphaQuest sold 42,909 Denali Therapeutics shares in Q1 2026, an estimated $708K.
AlphaQuest first reported a position in Denali Therapeutics in Q4 2023 and held it in 7 quarters.
AlphaQuest's Denali Therapeutics position peaked at $1.08M in Q3 2025.
269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.